|
A randomised, double-blind (sponsor unblinded), placebo-controlled, parallel-group, multicentre study to evaluate the efficacy and safety of GSK2269557 administered in addition to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease |
nemiralisib |
116678 |
NCT02294734 |
Pulmonary Disease, Chronic Obstructive |
Phase 2 |
|
|
|
|
The raw data are included within the analysis-ready data for this study and are not provided separately |
July 2021 |